Trial Profile
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Brazikumab (Primary) ; Brazikumab (Primary) ; Adalimumab
- Indications Crohn's disease
- Focus Biomarker; Therapeutic Use
- Acronyms INTREPID
- Sponsors AbbVie; Allergan; AstraZeneca; AstraZeneca AB
- 23 Nov 2023 This trial has been completed in Germany (global end date: 2023-10-18), according to European Clinical Trials Database.
- 20 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 06 Sep 2023 This trial has been discontinued in Spain (Date of the global end of the trial: 01-Jun-2023), according to the European Clinical Trials Database record.